- Company List - L
- LXEO
Insider Trading activities at Lexeo Therapeutics, Inc. (LXEO)
Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Lexeo Therapeutics, Inc. (LXEO)
since 2023 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Lexeo Therapeutics, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1907108.
Total stock buying since 2023: $12,499,982.
Total stock sales since 2023: $1,387,098.
Total stock option exercises since 2023: $81,550.
Table 1. Yearly summary of insider stock purchases, sales, and option exercises
at Lexeo Therapeutics, Inc. (LXEO).
|
Insider Buying |
Insider Sales |
Option Exercises |
| Year |
Shares | Value |
Shares | Value |
Shares | Value |
| 2025 | 0 | $0 | 19,934 | $85,603 | 0 | $0 |
| 2024 | 0 | $0 | 85,000 | $1,301,495 | 35,000 | $81,550 |
| 2023 | 1,136,362 | $12,499,982 | 0 | $0 | 0 | $0 |
Table 2. Monthly summary of insider trading at Lexeo Therapeutics, Inc. (LXEO).
| Trading Period |
Insider Buying |
Insider Sales |
Option Exercises |
| year-month |
Shares | Value |
Shares | Value |
Shares | Value |
| 2025-08 | 0 | $0 | 7,115 | $33,211 | 0 | $0 |
| 2025-05 | 0 | $0 | 2,547 | $7,064 | 0 | $0 |
| 2025-02 | 0 | $0 | 10,272 | $45,328 | 0 | $0 |
| 2024-12 | 0 | $0 | 2,500 | $20,492 | 2,500 | $5,825 |
| 2024-11 | 0 | $0 | 2,500 | $19,557 | 2,500 | $5,825 |
| 2024-10 | 0 | $0 | 5,000 | $40,495 | 5,000 | $11,650 |
| 2024-09 | 0 | $0 | 5,000 | $53,275 | 5,000 | $11,650 |
| 2024-08 | 0 | $0 | 5,000 | $57,634 | 5,000 | $11,650 |
| 2024-07 | 0 | $0 | 55,000 | $955,272 | 5,000 | $11,650 |
| 2024-06 | 0 | $0 | 5,000 | $88,675 | 5,000 | $11,650 |
| 2024-05 | 0 | $0 | 5,000 | $66,095 | 5,000 | $11,650 |
| 2023-11 | 1,136,362 | $12,499,982 | 0 | $0 | 0 | $0 |
Table 3. Detailed insider trading at Lexeo Therapeutics, Inc. (LXEO)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-08-18 | Otero Jose Manuel (Chief Technical Officer) | Sale | 2,848 | 4.67 | 13,294 |
| 2025-08-18 | See Tai Sandi (Chief Development Officer) | Sale | 382 | 4.67 | 1,783 |
| 2025-08-18 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 2,735 | 4.67 | 12,766 |
| 2025-08-18 | Robertson Jenny (Chief Legal Officer) | Sale | 542 | 4.67 | 2,530 |
| 2025-08-18 | Adler Eric (Chief Medical Officer) | Sale | 608 | 4.67 | 2,838 |
| 2025-05-16 | See Tai Sandi (Chief Development Officer) | Sale | 367 | 2.77 | 1,018 |
| 2025-05-16 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 1,074 | 2.77 | 2,979 |
| 2025-05-16 | Robertson Jenny (Chief Legal Officer) | Sale | 521 | 2.77 | 1,445 |
| 2025-05-16 | Adler Eric (Chief Medical Officer) | Sale | 585 | 2.77 | 1,622 |
| 2025-02-19 | See Tai Sandi (Chief Development Officer) | Sale | 1,486 | 4.41 | 6,557 |
| 2025-02-19 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 4,326 | 4.41 | 19,090 |
| 2025-02-19 | Robertson Jenny (Chief Legal Officer) | Sale | 2,101 | 4.41 | 9,271 |
| 2025-02-19 | Adler Eric (Chief Medical Officer) | Sale | 2,359 | 4.41 | 10,410 |
| 2024-12-10 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 2,500 | 8.20 | 20,492 |
| 2024-12-10 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 2,500 | 2.33 | 5,825 |
| 2024-11-11 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 2,500 | 7.82 | 19,557 |
| 2024-11-11 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 2,500 | 2.33 | 5,825 |
| 2024-10-10 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 5,000 | 8.10 | 40,495 |
| 2024-10-10 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 5,000 | 2.33 | 11,650 |
| 2024-09-10 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 5,000 | 10.65 | 53,275 |
| 2024-09-10 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 5,000 | 2.33 | 11,650 |
| 2024-08-12 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 5,000 | 11.53 | 57,634 |
| 2024-08-12 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 5,000 | 2.33 | 11,650 |
| 2024-07-11 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 28,031 | 18.06 | 506,239 |
| 2024-07-10 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 26,969 | 16.65 | 449,033 |
| 2024-07-10 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 5,000 | 2.33 | 11,650 |
| 2024-06-10 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 5,000 | 17.73 | 88,675 |
| 2024-06-10 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 5,000 | 2.33 | 11,650 |
| 2024-05-13 | Townsend Richard Nolan (Chief Executive Officer) | Sale | 5,000 | 13.22 | 66,095 |
| 2024-05-13 | Townsend Richard Nolan (Chief Executive Officer) | Option Ex | 5,000 | 2.33 | 11,650 |
| 2023-11-07 | Paster Anne-mari (10% Owner) | Buy | 454,545 | 11.00 | 4,999,995 |
| 2023-11-07 | Lundbeckfond Invest A/s (10% Owner) | Buy | 227,272 | 11.00 | 2,499,992 |
| 2023-11-07 | Enright Patrick G (10% Owner) | Buy | 454,545 | 11.00 | 4,999,995 |
Insider trading activities including stock purchases, stock sales, and option exercises
of LXEO listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Lexeo Therapeutics, Inc. (symbol LXEO,
CIK number 1907108) see
the Securities and Exchange Commission (SEC) website.